Acute myeloid leukaemia induced by mitoxantrone: case report

Arquivos de Neuro-Psiquiatria

Walter Oleschko Arruda¹  María Belén Montú¹  Marcelo De Souza R. De Oliveira¹  Ricardo Ramina¹ 

[1] ,Instituto de Neurologia de CuritibaCuritiba PR ,Brasil

关键词: multiple sclerosis;    mitoxantrone;    acute myeloblastic leukemia;    esclerose múltipla;    mitoxantrone;    leucemia mielóide aguda;   

DOI  :  10.1590/S0004-282X2005000200024

来源: SciELO

【 摘 要 】

Mitoxantrone (MX) is an immunosupressant drug used in secondarily progressive multiple sclerosis (SPMS) and in relapsing-remitting multiple sclerosis (RRMS). It has a leukemogenesis potential induced by cytogenetic abnormalities, though with a low incidence. Promyelocitic leukaemia (type M3) and other forms of acute myeloblastic leukaemias (M4 and M5) have been described in a few MS patients who received MX during their treatment. We describe a white female patient, 47 year-old, with SPMS (EDSS = 4) with 14 years of disease. She received MX during her disease and developed acute promyelocytic leukaemia (M3), with severe thrombocytopenia 30 months later. She ultimately died due to intracerebral hemorrhage. Other cases of treatment related to AML are reviewed and discussed.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License